var data={"title":"Dexmedetomidine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Dexmedetomidine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6000?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=dexmedetomidine-drug-information\" class=\"drug drug_general\">see &quot;Dexmedetomidine: Drug information&quot;</a> and <a href=\"topic.htm?path=dexmedetomidine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Dexmedetomidine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158352\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Precedex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158353\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Precedex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1008230\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Adrenergic Agonist Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Alpha-Adrenergic Agonist</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Sedative</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49725283\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Errors have occurred due to misinterpretation of dosing information. Maintenance dose expressed as mcg/kg/<b><span style=\"text-decoration: underline\">hour</span></b>. Individualize and titrate to desired clinical effect:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>ICU sedation</b>: Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Loading dose</i> (Optional): IV: 0.1 to 0.5 mcg/kg/dose over 10 to 20 minutes. Use of loading dose is dependent upon concomitant sedation agents and patient&rsquo;s current and desired level of sedation (Chyrsostomou 2014; O&rsquo;Mara 2012; Su 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Maintenance dose</i>: Continuous IV infusion: Initial: 0.1 to 0.3 mcg/kg/hour, adjust dose to desired level of sedation; reported titration was variable; however, many increased by 0.1 mcg/kg/hour as needed to desired level of sedation. Reported dose variable, usual reported range: 0.2 to 0.6 mcg/kg/hour. Maximum dose: 1.5 mcg/kg/hour (Bejian 2009; Chrysosotomou 2009; Chysosotomou 2014; O&rsquo;Mara 2009; O&rsquo;Mara 2012; Su 2016). Dosing based on two prospective pharmacokinetic studies, three retrospective studies, and a case report. In the largest retrospective study, 24 neonates (GA: 25.5 &plusmn; 1.7 weeks) received a loading dose of 0.5 mcg/kg followed by a continuous infusion of 0.3 mcg/kg/hour, doses were titrated by 0.1 mcg/kg/hour every 12 hours to desired sedation. Mean rate required was 0.6 mcg/kg/hour (range: 0.3 to 1.2 mcg/kg/hour). When compared to a historical case-controlled cohort, neonates who received dexmedetomidine required less adjunctive sedation compared to neonates who received fentanyl, and there was no difference in hemodynamic parameters between the groups (O&rsquo;Mara 2012). A prospective, multicenter, pharmacokinetic study evaluated the safety and efficacy of escalating dose levels of dexmedetomidine in 42 neonates (preterm: n=18, GA: 28 to &lt;36 weeks; term: n=24, GA: 36 to 44 weeks). Patients in each group were sequentially assigned to 1 of 3 escalating dose levels. Level 1 received a loading dose of 0.05 mcg/kg, then maintenance infusion of 0.05 mcg/kg/hour. Level 2 received a loading dose of 0.1 mcg/kg, then a maintenance infusion of 0.1 mcg/kg/hour. Level 3 received a loading dose of 0.2 mcg/kg, then a maintenance infusion of 0.2 mcg/kg/hour. Loading doses were administered over 10 to 20 minutes. Sedation was demonstrated at each dose but several patients in the Level 1 group had undetectable serum concentrations (Chrysostomou 2014). Reported incidence of adverse effects has been variable; although many studies report no occurrence of adverse events, a few studies have reported cases of hypotension and bradycardia leading to discontinuation of dexmedetomidine and in some cases requiring resuscitation measures (Chrysostomou 2009; Su 2106).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1008260\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=dexmedetomidine-drug-information\" class=\"drug drug_general\">see &quot;Dexmedetomidine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Errors have occurred due to misinterpretation of dosing information. Maintenance dose expressed as mcg/kg/<b><span style=\"text-decoration: underline\">hour</span></b>. Individualize and titrate to desired clinical effect. At recommended doses, dexmedetomidine does not provide adequate and reliable amnesia (when necessary); therefore, use of additional agents with amnestic properties (eg, benzodiazepines) may be necessary (Ebert 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatrics:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>ICU sedation</b>: Infants, Children, and Adolescents: Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Loading dose</i> (Optional): IV: 0.5 to 1 mcg/kg/dose over 10 minutes (Chrysostomou 2009; Walker 2006); use of loading dose is dependent upon concomitant sedation agents and patient&rsquo;s current and desired level of sedation</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Maintenance dose</i>: Continuous IV infusion: Initial: 0.2 to 0.5 mcg/kg/hour; adjust dose to desired level of sedation. Dosing based on multiple retrospective studies, case reports, and a few prospective studies. Most reported increasing by 0.1 to 0.3 mcg/kg/hour as needed. Reported maintenance dose variable, usual reported range was 0.4 to 0.7 mcg/kg/hour (Bejian 2009; Carroll 2008; Chrysostomou 2006; Chrysostomou 2009; Czaja 2009; Hosokawa 2010; Tobias 2004; Walker 2006; Whalen 2014). In general, infants may require higher maintenance infusion rates than either neonates or older children (Chrysostomou 2006; Chrysostomou 2009; Tobias 2004). Maximum reported doses varied; most utilized doses &lt;1 mcg/kg/hour; however, doses as high as 2.5 mcg/kg/hour in intubated patients have been described (Carroll 2008). Although the manufacturer recommends duration of infusion should not exceed 24 hours, most studies reported use beyond this time period; most patients received infusion for &le;72 hours; however, one patient received dexmedetomidine for 103 days (Whalen 2014). Prolonged infusions should not be abruptly discontinued and are generally tapered over several days to prevent withdrawal symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sedation/anesthesia, noninvasive procedures: </b>Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Loading dose</i>: Infants, Children, and Adolescents: IV: 0.5 to 2 mcg/kg/dose over 10 minutes; may be repeated if sedation is not adequate (Ahmed 2014; Berkenbosch 2005; Koroglu 2006; Mason 2013; Siddappa 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Maintenance dose</i>: Infants, Children, and Adolescents: Continuous IV infusion: 0.5 to 1 mcg/kg/hour (Ahmed 2014; Berkenbosch 2005; Koroglu 2006; Mason 2013; Siddappa 2011). Dosing based on multiple retrospective and prospective studies in over 800 pediatric patients receiving dexmedetomidine (&plusmn; other sedatives) for noninvasive procedures (eg, EEG, MRI, PET scan). In the largest, a retrospective study, 669 patients (age: 0.1 to 22.5 years) undergoing nuclear medicine imaging received dexmedetomidine for sedation. A bolus of 2 mcg/kg was administered over 10 minutes; this dose could be repeated up to 2 additional times if the predefined sedation score was not achieved; in addition, patients also received a maintenance infusion of 1 mcg/kg/hour. The mean time to achieve adequate sedation for all patients was 8.6 &plusmn; 4.6 minutes (range: 1 to 40 minutes). Hypotension, hypertension, and bradycardia occurred in 58.7%, 2.1% and 4.3% of patients, respectively; no patient required pharmacologic treatment. Hypotension and bradycardia were noted to be age related; risk of hypotension increased by 25% with each 5 year age increment increase and bradycardia occurred more often in children 3 to 12 years than any other age group. The authors concluded that the drug was well tolerated (Mason 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sedation, pre-anesthetic</b>: Limited data available: Children and Adolescents (very limited data available in patients &gt;9 years): Intranasal: 1 to 2 mcg/kg as a single dose 30 to 60 minutes prior to induction of anesthesia. Higher-end doses (2 mcg/kg) are recommended for older children (&ge; 5 years) and adolescents (Talon 2009; Yuen 2012). Dosing based on multiple prospective studies (Akin 2012; Cimen 2013; Talon 2009; Wang 2014; Yuen 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>ICU sedation</b>: IV: Initial: Loading infusion (optional; see <b>&ldquo;Note&rdquo;</b> below): 1 mcg/kg over 10 minutes, followed by a maintenance infusion (see<b> &ldquo;Note&rdquo;</b> below) of 0.2 to 0.7 mcg/kg/<b>hour</b>; adjust rate to desired level of sedation; titration no more frequently than every 30 minutes may reduce the incidence of hypotension (Gerlach 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note: </b>\n      <i>Loading infusion:</i> The loading dose may be omitted for this indication if patient is either being converted from another sedative and patient is adequately sedated or there are concerns for hemodynamic compromise. <i>Maintenance infusion:</i> Dosing ranges between 0.2 to 1.5 mcg/kg/<b>hour</b> have been reported during randomized controlled clinical trials (Pandharipande 2007; Riker 2009). Although infusion rates as high as 2.5 mcg/kg/<b>hour</b> have been used, it is thought that doses &gt;1.5 mcg/kg/<b>hour</b> do not add to clinical efficacy (Venn 2002). Manufacturer recommends duration of infusion should not exceed 24 hours; however, randomized clinical trials have demonstrated efficacy and safety comparable to lorazepam and midazolam with longer-term infusions of up to ~5 days (Pandharipande 2007; Riker 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Procedural sedation</b>: IV: Initial: Loading infusion of 1 mcg/kg (or 0.5 mcg/kg for less invasive procedures [eg, ophthalmic]) over 10 minutes, followed by a maintenance infusion of 0.6 mcg/kg/<b>hour</b>, titrate to desired effect; usual range: 0.2 to 1 mcg/kg/<b>hour</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Fiberoptic intubation (awake): IV: Initial: Loading infusion of 1 mcg/kg over 10 minutes, followed by a maintenance infusion of 0.7 mcg/kg/<b>hour</b> until endotracheal tube is secured</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b>There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, pharmacokinetics were not significantly different in adult patients with severe renal impairment (CrCl &lt;30 mL/minute).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Adults: There are no specific dosage adjustments provided in the manufacturer&rsquo;s labeling; however, consider a dose reduction. Clearance is reduced in varying degrees based on the level of hepatic impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158336\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 400 mcg/4 mL (4 mL); 1000 mcg/10 mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Precedex: 400 mcg/100 mL (100 mL); 200 mcg/2 mL (2 mL) [additive free, latex free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Precedex: 200 mcg/50 mL (50 mL) [latex free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Precedex: 80 mcg/20 mL (20 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mcg/2 mL (2 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158321\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1008265\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Administer using a controlled infusion device. Infuse loading dose over 10 minutes; may extend up to 20 minutes in neonatal patients or when needed to further reduce vasoconstrictive effects; rapid infusions are associated with severe side effects. Dexmedetomidine may adhere to natural rubber; use administration components made with synthetic or coated natural rubber gaskets.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intranasal: Administer undiluted (100 mcg/ml) or dilute in a small volume of NS (eg, to a total volume 1 or 1.5 mL). Divide dose and give half in each nostril by slowly dripping from a needleless syringe onto the nasal mucosa while in a recumbent position (Akin 2012; Cimen 2013; Wang 2014). Some recommend using a nasal atomizer such as the MAD Nasal Drug delivery device (Talon 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14471306\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 4 mcg/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6826832\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bottles: Store at room temperature.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vials: Store unopened vials (single-dose and multi-dose) at room temperature. Diluted solutions using multi-dose vials may be stored for up to 4 hours at room temperature or up to 24 hours at 2&deg;C to 8&deg;C (35&deg;F to 46&deg;F) prior to use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1008231\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting (FDA approved in adults); sedation of nonintubated patients prior to and/or during surgical or other procedures (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158379\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Precedex may be confused with Peridex</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Errors have occurred due to misinterpretation of dosing information; use caution. Maintenance dose expressed as mcg/kg/<b>hour</b>.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158376\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Atrial fibrillation, bradycardia, edema, hypertension, hypertension (diastolic), hypotension, hypovolemia, peripheral edema, systolic hypertension, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Agitation, anxiety</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Hyperglycemia, hypocalcemia, hypokalemia, hypoglycemia, hypomagnesemia, increased thirst</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Constipation, nausea, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Oliguria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Anemia</p>\n    <p style=\"text-indent:-4em;margin-left:4em;margin-right:2em;text-align:justify;\">Renal: Acute renal failure, decreased urine output</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Pleural effusion, respiratory depression, wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever, withdrawal syndrome (ICU sedation)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Abdominal pain, acidosis, apnea, atrioventricular block, bronchospasm, cardiac arrhythmia, cardiac disease, chills, confusion, convulsions, decreased visual acuity, delirium, diaphoresis, diarrhea, dizziness, drug tolerance (use &gt;24 hours), dyspnea, extrasystoles, hallucination, headache, heart block, hemorrhage, hepatic insufficiency, hyperbilirubinemia, hypercapnia, hyperkalemia, hypernatremia, hyperpyrexia, hypoventilation, hypoxia, illusion, increased blood urea nitrogen, increased gamma-glutamyl transferase, increased serum alkaline phosphatase, increased serum ALT, increased serum AST, inversion T-wave on ECG, myocardial infarction, neuralgia, neuritis, pain, photopsia, polyuria, prolonged Q-T interval on ECG, pulmonary congestion, respiratory acidosis, rigors, seizure, sinoatrial arrest, speech disturbance, supraventricular tachycardia, tachyphylaxis (use &gt;24 hours), variable blood pressure, ventricular arrhythmia, ventricular tachycardia, visual disturbance, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158341\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the U.S. manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Hypersensitivity to dexmedetomidine or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158325\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular effects: Episodes of bradycardia, hypotension, and sinus arrest have been associated with rapid IV administration (eg, bolus administration) or when given to patients with high vagal tone. When used for ICU sedation, use of a loading dose is optional; for the maintenance infusion, titration no more frequently than every 30 minutes may reduce the incidence of hypotension (Gerlach 2009). If medical intervention is required, treatment may include stopping or decreasing the infusion, increasing the rate of IV fluid administration, use of pressor agents, and elevation of the lower extremities. At low concentrations, mean arterial pressure (MAP) may be reduced without changes in other hemodynamic parameters (eg, pulmonary artery occlusion pressure [PAOP]); however, at higher concentrations (&gt;1.9 ng/mL), MAP, CVP, PAOP, PVR, and SVR increase (Ebert 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Transient hypertension: Has been primarily observed during loading dose administration and is associated with the initial peripheral vasoconstrictive effects of dexmedetomidine. Treatment is generally unnecessary; however, reduction of infusion rate may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with heart block, bradycardia, severe ventricular dysfunction, hypovolemia, or chronic hypertension. In a scientific statement from the American Heart Association, dexmedetomidine has been determined to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: moderate) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; cardiovascular adverse events (eg, bradycardia, hypotension) may be more pronounced.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage reductions recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; cardiovascular events (eg, bradycardia, hypotension) may be more pronounced. Dose reduction may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Arousability: Patients may be arousable and alert when stimulated. This alone should not be considered as lack of efficacy in the absence of other clinical signs/symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced personnel: Should be administered only by persons skilled in management of patients in intensive care setting or operating room. Patients should be continuously monitored.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tolerance and tachyphylaxis: Use of infusions &gt;24 hours has been associated with tolerance and tachyphylaxis and dose-related increase in adverse reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: When withdrawn abruptly in patients who have received &gt;24 hours of therapy, withdrawal symptoms may result (eg, hypertension, tachycardia, nervousness, nausea, vomiting, agitation, headaches). Use for &gt;24 hours is not recommended by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158366\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2A6 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158330\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13128&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: Alpha2-Agonists may enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the Alpha2-Agonist is abruptly withdrawn.  Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.<b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bretylium: May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2A6 Inhibitors (Moderate): May decrease the metabolism of CYP2A6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2A6 Inhibitors (Strong): May decrease the metabolism of CYP2A6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Alpha2-Agonists may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: May diminish the antihypertensive effect of Alpha2-Agonists. Management: Consider avoiding concurrent use.  If the combination cannot be avoided, monitor for decreased effects of alpha2-agonists if mirtazapine is initiated/dose increased, or increased effects if mirtazapine is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents. Management: Ruxolitinib Canadian product labeling recommends avoiding use with bradycardia-causing agents to the extent possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin/Norepinephrine Reuptake Inhibitors: May diminish the antihypertensive effect of Alpha2-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terlipressin: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May diminish the antihypertensive effect of Alpha2-Agonists.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158332\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6826804\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects have been observed in some animal reproduction studies. Dexmedetomidine is expected to cross the placenta. Information related to use during pregnancy is limited (El-Tahan 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1008267\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Level of sedation, heart rate, respiration, ECG, blood pressure, pain control</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158324\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Selective alpha<sub>2</sub>-adrenoceptor agonist with anesthetic and sedative properties thought to be due to activation of G-proteins by alpha<sub>2a</sub>-adrenoceptors in the brainstem resulting in inhibition of norepinephrine release; peripheral alpha<sub>2b</sub>-adrenoceptors are activated at high doses or with rapid IV administration resulting in vasoconstriction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158340\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV loading dose: 5 to 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intranasal: 45 to 60 minutes (Yuen 2007), may be faster in pediatric patients when administered via an atomizing device (Talon 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peak effect:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV loading dose: 15 to 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intranasal: 90 to 105 minutes (Yuen 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration (dose dependent): 60 to 120 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>ss</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preterm Neonates (28 to &lt;36 weeks GA): 2.7 L/kg (range: 2.5 to 5.9 L/kg) (Chrysostomou 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Term neonates (36 to &le;44 weeks GA): 3.9 L/kg (range: 0.1 to 10.9 L/kg) (Chrysostomou 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children &lt;2 years: Median: 3.8 L/kg (range: 1.9 to 4.6 L/kg) (Vilo 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to 11 years: Median: 2.2 L/kg (range: 1.3 to 2.8 L/kg) (Vilo 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: ~118 L; rapid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Intranasal: Variable: Median: 65% (range: 35% to 93%) (Iirola 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~94%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via N-glucuronidation, N-methylation, and CYP2A6</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preterm Neonates (28 to &lt;36 weeks GA): Terminal: 7.6 hours (range: 3 to 9.1 hours) (Chrysostomou 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Term Neonates (36 to &le;44 weeks GA): Terminal: Median: 3.2 hours (range: 1 to 9.4 hours) (Chrysostomou 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children &lt;2 years: Terminal: Median: 2.3 hours (range: 1.5 to 3.3 hours) (Vilo 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to 11 years: Terminal: Median: 1.6 hours (range: 1.2 to 2.3 hours) (Vilo 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Distribution: ~6 minutes; Terminal: ~up to 3 hours (Venn 2002); significantly prolonged in patients with severe hepatic impairment (Cunningham 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Intranasal: Median: 38 minutes (range: 15 to 60 minutes) (Iirola 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (95%); feces (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clearance:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Clearance following cardiac surgery was reduced by 27% in pediatric patients aged 1 week to 14 years (Potts 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Preterm Neonates (28 to &lt;36 weeks GA): 0.3 L/hour/kg (0.2 to 0.4 L/hour/kg) (Chrysostomou 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Term Neonates (36 to &le;44 weeks GA): 0.9 L/hour/kg (0.2 to 1.5 L/hour/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &lt;2 years: Median: 1 L/hour/kg (0.85 to 1.66 L/hour/kg) (Vilo 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 2 to 11 years: Median: 1 L/hour/kg (0.56 to 1.35 L/hour/kg) (Vilo 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: ~39 L/hour; Hepatic impairment (Child-Pugh class A, B, or C): Mean clearance values were 74%, 64%, and 53% respectively, of those observed in healthy adults</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2890154\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">In a prospective, cohort study of pediatric patients undergoing cardiothoracic surgery for congenital heart disease, patients received perioperative sedation with either dexmedetomidine (n=32, median age: 4.8 months, range: ~1 week to 16.5 years) or standard therapy. Patients receiving dexmedetomidine were noted to have significantly fewer postoperative arrhythmias (0% vs 25% for ventricular arrhythmias, p=0.01; 6% vs 25% for supraventricular arrhythmias, p=0.05) (Chrysostomou 2011). Further studies are needed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323099\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Dexmedetomidine HCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg/2 mL (2 mL): $22.91</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400MCG/4ML (4 mL): $94.74</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000MCG/10ML (10 mL): $233.94</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Precedex Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mcg/20 mL (20 mL): $31.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg/2 mL (2 mL): $50.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg/50 mL (50 mL): $55.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mcg/100 mL (100 mL): $100.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158343\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cepedex (AT);</li>\n      <li>Demesynt (CR, DO, GT, HN, PA, SV);</li>\n      <li>Demsynt (NI);</li>\n      <li>Detomax IV (BD);</li>\n      <li>Dexdomitor (AT);</li>\n      <li>Dexdor (AT, DK, ES, HR, HU, IE, LT, LV, MT, NL, PL, RO, TR, UA);</li>\n      <li>Dexem (LK);</li>\n      <li>Meproxidina (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Precedex (AE, AR, AU, BH, BR, CR, CZ, DO, GT, HK, HN, ID, JO, KR, KW, LB, MX, MY, NI, NZ, PA, PE, PH, QA, SA, SG, SV, TH, TW, UY, VN);</li>\n      <li>Sedadex (AT)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahmed SS, Unland T, Slaven JE, Nitu ME, Rigby MR. Successful use of intravenous dexmedetomidine for magnetic resonance imaging sedation in autistic children. <i>South Med J</i>. 2014;107(9):559-564.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/25188619/pubmed\" target=\"_blank\" id=\"25188619\">25188619</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Akin A, Bayram A, Esmaoglu A, et al. Dexmedetomidine vs midazolam for premedication of pediatric patients undergoing anesthesia. <i>Paediatr Anaesth</i>. 2012;22(9):871-876.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/22268591/pubmed\" target=\"_blank\" id=\"22268591\">22268591</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bejian S, Valasek C, Nigro JJ, Cleveland DC, Willis BC. Prolonged use of dexmedetomidine in the paediatric cardiothoracic intensive care unit. <i>Cardiol Young</i>. 2009;19(1):98-104.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/19154626/pubmed\" target=\"_blank\" id=\"19154626\">19154626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berkenbosch JW, Wankum PC, and Tobias JD, &quot;Prospective Evaluation of Dexmedetomidine for Noninvasive Procedural Sedation in Children,&quot; <i>Pediatr Crit Care Med</i>, 2005, 6(4):435-9.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carroll CL, Krieger D, Campbell M, Fisher DG, Comeau LL, Zucker AR. Use of dexmedetomidine for sedation of children hospitalized in the intensive care unit. <i>J Hosp Med</i>. 2008;3(2):142-147.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/18438790/pubmed\" target=\"_blank\" id=\"18438790\">18438790</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chrysostomou C, Di Filippo S, Manrique AM, et al, &quot;Use of Dexmedetomidine in Children After Cardiac and Thoracic Surgery,&quot; <i>Pediatr Crit Care Med</i>, 2006, 7(2):126-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/16446599 /pubmed\" target=\"_blank\" id=\"16446599 \">16446599 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chrysostomou C, Sanchez De Toledo J, Avolio T, et al. Dexmedetomidine use in a pediatric cardiac intensive care unit: can we use it in infants after cardiac surgery? <i>Pediatr Crit Care Med</i>. 2009;10(6):654-660.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/16446599 /pubmed\" target=\"_blank\" id=\"16446599 \">16446599 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chrysostomou C, Sanchez-de-Toledo J, Wearden P, et al. Perioperative use of dexmedetomidine is associated with decreased incidence of ventricular and supraventricular tachyarrhythmias after congenital cardiac operations. <i>Ann Thorac Surg</i>. 2011;92(3):964-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/21871284/pubmed\" target=\"_blank\" id=\"21871284\">21871284</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chrysostomou C, Schulman SR, Herrera Castellanos M, et al. A phase II/III, multicenter, safety, efficacy, and pharmacokinetic study of dexmedetomidine in preterm and term neonates. <i>J Pediatr</i>. 2014;164(2):276-282.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/24238862/pubmed\" target=\"_blank\" id=\"24238862\">24238862</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cimen ZS, Hanci A, Sivrikaya GU, Kilinc LT, Erol MK. Comparison of buccal and nasal dexmedetomidine premedication for pediatric patients. <i>Paediatr Anaesth</i>. 2013;23(2):134-138.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/22985207/pubmed\" target=\"_blank\" id=\"22985207\">22985207</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cunningham FE, Baughman VL, Tonkovich L, et al. Pharmacokinetics of dexmedetomidine (DEX) in patients with hepatic failure (HF). <i>Clin Pharmacol Ther.</i> 1999;65:128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/24238862/pubmed\" target=\"_blank\" id=\"24238862\">24238862</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Czaja AS, Zimmerman JJ. The use of dexmedetomidine in critically ill children. <i>Pediatr Crit Care Med</i>. 2009;10(3):381-386.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/19325505/pubmed\" target=\"_blank\" id=\"19325505\">19325505</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ebert TJ, Hall JE, Barney JA, et al. The effects of increasing plasma concentrations of demedetomidine in humans. <i>Anesthesiology</i>. 2000;93:382-394.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/19325505/pubmed\" target=\"_blank\" id=\"19325505\">19325505</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    El-Tahan MR, Mowafi HA, Al Sheikh IH, et al, &quot;Efficacy of Dexmedetomidine in Suppressing Cardiovascular and Hormonal Responses to General Anaesthesia for Caesarean Delivery: A Dose-Response Study,&quot; <i>Int J Obstet Anesth</i>, 2012, 21(3):222-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/22681971/pubmed\" target=\"_blank\" id=\"22681971\">22681971</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gerlach AT, Dasta JF, Steinberg S, Martin LC, Cook CH. A new dosing protocol reduces dexmedetomidine-associated hypotension in critically ill surgical patients. <i>J Crit Care</i>. 2009;24(4):568-574.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/19682844/pubmed\" target=\"_blank\" id=\"19682844\">19682844</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hosokawa K, Shime N, Kato Y, et al. Dexmedetomidine sedation in children after cardiac surgery. <i>Pediatr Crit Care Med</i>. 2010;11(1):39-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/19593247/pubmed\" target=\"_blank\" id=\"19593247\">19593247</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Iirola T, Vilo S, Manner T, et al. Bioavailability of dexmedetomidine after intranasal administration. <i>Eur J Clin Pharmacol</i>. 2011;67(8):825-831.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/21318594/pubmed\" target=\"_blank\" id=\"21318594\">21318594</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koroglu A, Teksan H, Sagir O, Yucel A, Toprak HI, Ersoy OM. A comparison of the sedative, hemodynamic, and respiratory effects of dexmedetomidine and propofol in children undergoing magnetic resonance imaging. <i>Anesth Analg</i>. 2006;103(1):63-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/16790627/pubmed\" target=\"_blank\" id=\"16790627\">16790627</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mason KP, Robinson F, Fontaine P, Prescilla R. Dexmedetomidine offers an option for safe and effective sedation for nuclear medicine imaging in children. <i>Radiology</i>. 2013;267(3):911-917.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/23449958/pubmed\" target=\"_blank\" id=\"23449958\">23449958</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Mara K, Gal P, Ransommd JL, et al. Successful use of dexmedetomidine for sedation in a 24-week gestational age neonate. <i>Ann Pharmacother</i>. 2009;43(10):1707-1713.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/19755621/pubmed\" target=\"_blank\" id=\"19755621\">19755621</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Mara K, Gal P, Wimmer J, et al. Dexmedetomidine versus standard therapy with fentanyl for sedation in mechanically ventilated premature neonates. <i>J Pediatr Pharmacol Ther</i>. 2012;17(3):252-262.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/23258968/pubmed\" target=\"_blank\" id=\"23258968\">23258968</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. <i>Circulation</i>. 2016;134(6):e32-69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/23258968/pubmed\" target=\"_blank\" id=\"23258968\">23258968</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pandharipande PP, Pun BT, Herr DL, et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. <i>JAMA</i>. 2007;298(22):2644-2653.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/18073360/pubmed\" target=\"_blank\" id=\"18073360\">18073360</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phan H and Nahata MC, &quot;Clinical Uses of Dexmedetomidine in Pediatric Patients,&quot; <i>Paediatr Drugs</i>, 2008, 10(1):49-69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/18162008/pubmed\" target=\"_blank\" id=\"18162008\">18162008</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Potts AL, Anderson BJ, Warman GR, Lerman J, Diaz SM, Vilo S. Dexmedetomidine pharmacokinetics in pediatric intensive care--a pooled analysis. <i>Paediatr Anaesth</i>. 2009;19(11):1119-1129.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/18162008/pubmed\" target=\"_blank\" id=\"18162008\">18162008</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Precedex (dexmedetomidine) [prescribing information]. Lake Forest, IL: Hospira Inc; April 2016.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/18162008/pubmed\" target=\"_blank\" id=\"18162008\">18162008</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Riker RR, Shehabi Y, Bokesch PM, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. <i>JAMA</i>. 2009;301(5):489-499.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/19188334/pubmed\" target=\"_blank\" id=\"19188334\">19188334</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Siddappa R, Riggins J, Kariyanna S, Calkins P, Rotta AT. High-dose dexmedetomidine sedation for pediatric MRI. <i>Paediatr Anaesth</i>. 2011;21(2):153-158.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/21210884/pubmed\" target=\"_blank\" id=\"21210884\">21210884</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Su F, Gastonguay MR, Nicolson SC, DiLiberto M, Ocampo-Pelland A, Zuppa AF. Dexmedetomidine pharmacology in neonates and infants after open heart surgery. <i>Anesth Analg</i>. 2016;122(5):1556-1566.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/26218862/pubmed\" target=\"_blank\" id=\"26218862\">26218862</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Talon MD, Woodson LC, Sherwood ER, Aarsland A, McRae L, Benham T. Intranasal dexmedetomidine premedication is comparable with midazolam in burn children undergoing reconstructive surgery. <i>J Burn Care Res</i>. 2009;30(4):599-605.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/19506498/pubmed\" target=\"_blank\" id=\"19506498\">19506498</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tobias JD, Berkenbosch JW. Sedation during mechanical ventilation in infants and children: dexmedetomidine versus midazolam. <i>South Med J</i>. 2004;97(5):451-455.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/15180019/pubmed\" target=\"_blank\" id=\"15180019\">15180019</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Venn RM, Karol MD, Grounds RM. Pharmacokinetics of dexmedetomidine infusions for sedation of postoperativepatients requiring intensive care. <i>Br J Anaesth</i>. 2002;88(5):669-675.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/12067004/pubmed\" target=\"_blank\" id=\"12067004\">12067004</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vilo S, Rautiainen P, Kaisti K, et al. Pharmacokinetics of intravenous dexmedetomidine in children under 11 yr of age. <i>Br J Anaesth</i>. 2008;100(5):697-700.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/18378546/pubmed\" target=\"_blank\" id=\"18378546\">18378546</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walker J, Maccalum M, Fischer C, et al, &quot;Sedation Using Dexmedetomidine in Pediatric Burn Patients,&quot; <i>J Burn Care Res</i>, 2006, 27(2):206-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/16566567/pubmed\" target=\"_blank\" id=\"16566567\">16566567</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wang SS, Zhang MZ, Sun Y, et al. The sedative effects and the attenuation of cardiovascular and arousal responses during anesthesia induction and intubation in pediatric patients: a randomized comparison between two different doses of preoperative intranasal dexmedetomidine. <i>Paediatr Anaesth</i>. 2014;24(3):275-281.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/24224515/pubmed\" target=\"_blank\" id=\"24224515\">24224515</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Whalen LD, Di Gennaro JL, Irby GA, Yanay O, Zimmerman JJ. Long-term dexmedetomidine use and safety profile among critically ill children and neonates. <i>Pediatr Crit Care Med</i>. 2014;15(8):706-714.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/25068249/pubmed\" target=\"_blank\" id=\"25068249\">25068249</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yuen VM, Hui TW, Irwin MG, et al. A randomised comparison of two intranasal dexmedetomidine doses for premedication in children. <i>Anaesthesia</i>. 2012;67(11):1210-1216.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/22950484/pubmed\" target=\"_blank\" id=\"22950484\">22950484</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yuen VM, Irwin MG, Hui TW, Yuen MK, Lee LH. A double-blind, crossover assessment of the sedative and analgesic effects of intranasal dexmedetomidine. <i>Anesth Analg</i>. 2007;105(2):374-380.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-pediatric-drug-information/abstract-text/17646493/pubmed\" target=\"_blank\" id=\"17646493\">17646493</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13128 Version 147.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F158352\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F158353\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1008230\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F49725283\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1008260\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F158336\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F158321\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1008265\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14471306\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F6826832\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1008231\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F158379\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F158376\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F158341\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F158325\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F158366\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F158330\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F158332\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6826804\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1008267\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F158324\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F158340\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F2890154\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323099\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F158343\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13128|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=dexmedetomidine-drug-information\" class=\"drug drug_general\">Dexmedetomidine: Drug information</a></li><li><a href=\"topic.htm?path=dexmedetomidine-patient-drug-information\" class=\"drug drug_patient\">Dexmedetomidine: Patient drug information</a></li></ul></div></div>","javascript":null}